South Korea Gene Therapy Market Introduction and Overview
According to SPER Market Research, the South Korea Gene Therapy Market is estimated to reach USD 15.33 million by 2033 with a CAGR 16.89%.
The report includes an in-depth analysis of the South Korea Gene Therapy Market, including market size and trends, product mix, distribution channels, and supplier analysis. Gene therapy is a medical procedure that involves changing, deleting, or adding particular genes to a patient's cells in order to address genetic problems. Targeting the underlying genetic cause, this therapeutic approach has the potential to treat hereditary disorders like cancer or cystic fibrosis. It has demonstrated positive outcomes in clinical trials and holds potential for personalized therapy.
- The Swiss Agency for Therapeutic Products approved Libmeldy in December 2023 to treat early-onset metachromatic leukodystrophy, which was a major step toward meeting the therapeutic demands of this uncommon condition.
Market Opportunities and Challenges
Opportunities: The country's increased frequency of genetic and chronic diseases and disorders, government activities, approvals, and major technological developments in genomic medicines all contribute to the market's growth. Gene therapy is a revolutionary method of treating illnesses by altering genetic material to replace or fix damaged genes. Increased investment in research and development, the incidence of chronic diseases and genetic abnormalities, and scientific breakthroughs have all contributed to the considerable uptake of this novel therapeutic approach in South Korea. Furthermore, Products involving gene therapy must pass stringent regulatory review before being approved. They produce longer-lasting and more powerful therapeutic effects than conventional medications by acting at the genetic level. This significant benefit that gene therapy products provide has been seen to contribute to an increase in the number of approvals that these treatments have gotten. Between 2021 and 2023, over ten products were authorized by the US FDA. Additionally, a sizable number of clinically developed medications are anticipated to obtain final approval throughout the projection period. Thus, during the projection period, this is a key element propelling the market's expansion.
Challenges: A lot of research and development is being done to provide cutting-edge treatments like gene therapy. As a result, they require a substantial time and financial commitment. Clinical trials, preclinical testing, laboratory research, and regulatory approval are all included in the expenses. Additionally, vectors used in gene therapy products must be created and individually developed according to specifications. The entire production process becomes more complex as a result. Production expenses are raised by the need for strict adherence to quality standards and carefully controlled manufacturing processes. Additionally, gene therapies are not mass-produced and are highly focused treatments. All of these elements contribute to the high price of gene therapy products, which hinders their uptake, particularly in underdeveloped nations.
Market Competitive Landscape
The Gene Therapy market is moderately fragmented in South Korea. Some of the market players are CHA Biotech Co., Ltd., CORESTEMCHEMON Inc., Ferring International Center S.A., HELIXMITH Co., Ltd., MEDIPOST Co., Ltd., Novartis Korea Ltd., PHARMICELL Co., Ltd., Rznomics Inc., S-Biomedic, Tego Science, Inc.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2020-2033 |
| Base year considered | 2023 |
| Forecast period | 2024-2033 |
| Segments covered | By Vector Type, By Method, By Gene Type, By Application, By End User |
| Regions covered | Eastern, Western, Northern, Southern |
| Companies Covered | CHA Biotech Co., Ltd., CORESTEMCHEMON Inc., Ferring International Center S.A., HELIXMITH Co., Ltd., MEDIPOST Co., Ltd., Novartis Korea Ltd., PHARMICELL Co., Ltd., Rznomics Inc., S-Biomedic, Tego Science, Inc. |
COVID-19 Impact on South Korea Gene Therapy Market
The South Korean gene therapy market was significantly impacted by the COVID-19 pandemic, which caused disruptions in a number of different domains. Clinical trials were halted, research facilities were restricted, and research and development (R&D) efforts were significantly delayed. As a result, ongoing research was slowed down, patient recruitment was restricted, and advancements in gene therapy were impeded. The supply chain for gene therapy goods was also impacted, as lockdowns and travel restrictions caused production difficulties and raw material shortages. Due to economic uncertainties that made investors more cautious and the fact that government and private sector resources were frequently diverted to COVID-19 response efforts, the pandemic resulted in a decrease in financial investments in the sector.
Key Target Audience:
- Individual Pharmaceutical and Biotech Companies
- Healthcare Providers and Hospitals
- Regulatory Authorities
- Researchers and Academics
- Gene Therapy Manufacturers
- Investors and Venture Capitalists
- Patients and Patient Advocacy Groups
- Government and Public Health Agencies
Our in-depth analysis of the South Korea Gene Therapy Market includes the following segments:
| By Vector Type: | Viral VectorNon-Viral Vector |
| By Method: | Insurance Agents/ BrokersEx-VivoIn-Vivo |
| By Gene Type: | AntigenCytokineTumor SuppressorSuicideDeficiencyGrowth factorsReceptorsOthers |
| By Application: | Oncological DisordersCardiovascular DiseasesInfectious DiseasesRare DiseasesNeurological DisordersOther Diseases |
| By End User: | Cancer InstitutesHospitalsResearch institutesOthers |
Key Topics Covered in the Report:
- South Korea Gene Therapy Market Size (FY’2024-FY’2033)
- Overview of South Korea Gene Therapy Market
- Segmentation of South Korea Gene Therapy Market By Vector Type (Viral Vector, Non-Viral Vector)
- Segmentation of South Korea Gene Therapy Market By Method (Ex-Vivo, In-Vivo)
- Segmentation of South Korea Gene Therapy Market By Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others)
- Segmentation of South Korea Gene Therapy Market By Application (Ocological Disorders, Cardiovascular Diseases, Infectious Diseases, Rare Diseases, Neurological Disorders, Other Diseases)
- Expansion Analysis of South Korea Gene Therapy Market
- Problems and Obstacles in South Korea Gene Therapy Market
- Competitive Landscape in the South Korea Gene Therapy Market
- Impact of COVID-19 and Demonetization on South Korea Gene Therapy Market
- Details on Current Investment in South Korea Gene Therapy Market
- Competitive Analysis of South Korea Gene Therapy Market
- Prominent Players in the South Korea Gene Therapy Market
- SWOT Analysis of South Korea Gene Therapy Market
- South Korea Gene Therapy Market Future Outlook and Projections (FY’2024-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the South Korea Gene Therapy Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. South Korea Gene Therapy Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in South Korea Gene Therapy Market
7. South Korea Gene Therapy Market, By Vector Type (USD Million) 2020-2033
7.1. South Korea Gene Therapy Market Size, Share and Forecast, By Vector Type, 2020-2026
7.2. South Korea Gene Therapy Market Size, Share and Forecast, By Vector Type, 2027-2033
7.3. Viral Vector
7.4. Non-Viral Vector
8. South Korea Gene Therapy Market, By Method (USD Million) 2020-2033
8.1. South Korea Gene Therapy Market Size, Share and Forecast, By Method, 2020-2026
8.2. South Korea Gene Therapy Market Size, Share and Forecast, By Method, 2027-2033
8.3. Insurance Agents/ Brokers
8.4. Ex-Vivo
8.5. In-Vivo
9. South Korea Gene Therapy Market, By Gene Type (USD Million) 2020-2033
9.1. South Korea Gene Therapy Market Size, Share and Forecast, By Gene Type, 2020-2026
9.2. South Korea Gene Therapy Market Size, Share and Forecast, By Gene Type, 2027-2033
9.3. Antigen
9.4. Cytokine
9.5. Tumor Suppressor
9.6. Suicide
9.7. Deficiency
9.8. Growth factors
9.9. Receptors
9.10. Others
10. South Korea Gene Therapy Market, By Application (USD Million) 2020-2033
10.1. South Korea Gene Therapy Market Size, Share and Forecast, By Application, 2020-2026
10.2. South Korea Gene Therapy Market Size, Share and Forecast, By Application, 2027-2033
10.3. Oncological Disorders
10.4. Cardiovascular Diseases
10.5. Infectious Diseases
10.6. Rare Diseases
10.7. Neurological Disorders
10.8. Other Diseases
11. South Korea Gene Therapy Market, By End User (USD Million) 2020-2033
11.1. South Korea Gene Therapy Market Size, Share and Forecast, By End User, 2020-2026
11.2. South Korea Gene Therapy Market Size, Share and Forecast, By End User, 2027-2033
11.3. Cancer Institutes
11.4. Hospitals
11.5. Research institutes
11.6. Others
12. South Korea Gene Therapy Market Forecast, 2020-2033 (USD Million)
12.1. South Korea Gene Therapy Market Size and Market Share
13. South Korea Gene Therapy Market, By Region, 2020-2033 (USD Million)
13.1. South Korea Gene Therapy Market Size and Market Share By Region (2020-2026)
13.2. South Korea Gene Therapy Market Size and Market Share By Region (2027-2033)
13.3. Eastern Region
13.4. Western Region
13.5. Southern Region
13.6. Northern Region
14. Company Profile
14.1. CHA Biotech Co., Ltd.
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. CORESTEMCHEMON Inc.
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Ferring International Center S.A.
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4. HELIXMITH Co., Ltd.
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. MEDIPOST Co., Ltd.
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4. Recent developments
14.6. Novartis Korea Ltd.
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. PHARMICELL Co., Ltd.
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Rznomics Inc.
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. S-Biomedic
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. Tego Science, Inc.
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11. Others
15. Conclusion
16. Reference Links
17. List of Abbreviations